Le Lézard
Classified in: Health
Subjects: PER, TRI

Clinovo taps Life Sciences executive Nandish Poluru as its next Chief Executive Officer


SAN JOSE, Calif., Aug. 18, 2022 /PRNewswire/ -- Clinovo, a technology focused Clinical services provider that accelerates Clinical Development for Life Sciences industry appoints Nandish Poluru as Chief Executive Officer effective immediately.

As an executive at the intersection of Lifesciences, Operations and Technology, Nandish has over two decades of experience in successfully accelerating Research and Development efforts for multiple companies across the Lifesciences industry. He brings expertise across the pharmaceutical value chain including Clinical Development and Operations, Clinical Data Management, Biostatistics and programming, Pharmacovigilance, Regulatory operations and Technology.

Most recently, Nandish was the Vice President of Clinical Innovation at Bristol Myers Squibb (BMS) where he led efforts to accelerate Clinical Research globally with a focus on Digital Health, Patient Centricity, and Speed to Market. During his tenure at BMS, he also served in various roles to modernize Clinical Development through process and digital solutions. Prior to BMS, Nandish was Executive Director at Allergan (an Abbvie company) and worked at Forest Laboratories in various roles. He also worked in Silicon Valley at the start of his career.

"It is with great excitement and immense pleasure that I welcome Nandish to Clinovo" said Vamsi Maddipatla, President and Chairman at Clinovo. "Nandish is a visionary and innovative leader who brings demonstrated experience and skills along with exceptional leadership abilities. He is uniquely positioned to lead us in our next phase of growth and establish Clinovo as a global leader in the Clinical solutions market".

"I am very excited to join and work with the talented team at Clinovo" said Nandish. "I am thrilled to build on the strong foundations already established and lead the company to further scale the capabilities. I strongly believe that Clinovo is well positioned to create value for our customers by accelerating Clinical trials globally and bring new medicines to market faster."

Nandish has an MBA from Yale school of Management with a focus on Healthcare Management. He also has a Master's in information systems from Cleveland State University and a Bachelor`s in Electrical Engineering from Sri Venkateswara University, India.

About Clinovo

Clinovo works with life sciences customers across the globe to accelerate clinical development and bring new medicines to market faster. Together with their customers, they focus on speed to submissions, decrease clinical development cycle times and lower development costs.

SOURCE Clinovo


These press releases may also interest you

at 08:17
AMIGOS FOR KIDS, a Miami nonprofit organization founded in 1991, is dedicated to preventing child abuse and neglect by valuing children, strengthening families and educating communities. ...

at 08:15
Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount....

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...



News published on and distributed by: